The role of the cytochrome P450 polymorphisms in clopidogrel efficacy and clinical utility

Current Medicinal Chemistry

Volumn 18, Issue 3, 2011, Pages 427-438

  Tousoulis, D ^a   Siasos, G ^a   Zaromytidou, M ^a   Papageorgiou, N ^a   Stefanadi, E ^a   Oikonomou, E ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clopidogrel resistance; Cytochrome P450; Gene polymorphisms; Platelets

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450; PRASUGREL;

ACUTE CORONARY SYNDROME; ARTICLE; BODY MASS; DRUG ABSORPTION; DRUG INTERACTION; GENETIC POLYMORPHISM; HUMAN; INSULIN RESISTANCE; PROTEIN POLYMORPHISM; STENT THROMBOSIS; THROMBOCYTE AGGREGATION;

EID: 79251560024     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794839151     Document Type: Article

References (117)

1. Antoniades, C.; Tousoulis, D.; Vasiliadou, C.; Stefanadi, E.; Marinou, K.; Stefanadis, C. Genetic polymorphisms of platelet glycol protein Ia and the risk for premature myocardial infarction: Effects on the release of sCD40L during the acute phase of premature myocardial infarction. J. Am. Coll. Cardiol., 2006, 47, 1959-66.
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348, 1329-39.
3. Yusuf, S.; Zhao, F.; Mehta, S.R.; Chrolavicius, S.; Tognoni, G.; Fox, K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 2001, 345, 494-502.
4. Beinart, S.C.; Kolm, P.; Veledar, E.; Zhang, Z.; Mahoney, E.M.; Bouin, O.; Gabriel, S.; Jackson, J.; Chen, R.; Caro, J.; Steinhubl, S.; Topol, E.; Weintraub, W.S. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: From the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J. Am. Coll. Cardiol., 2005, 46, 761-9.
5. Sabatine, M.S.; Cannon, C.P.; Gibson, C.M.; López-Sendón, J.L.; Montalescot, G.; Theroux, P.; Claeys, M.J.; Cools, F.; Hill, K.A.; Skene, A.M.; McCabe, C.H.; Braunwald, E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med., 2005, 352, 1179-89.
6. Chen, Z.M.; Jiang, L.X.; Chen, Y.P.; Xie, J.X.; Pan, H.C.; Peto, R.; Collins, R; Liu, L.S. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebocontrolled trial. Lancet, 2005, 366, 1607-21.
7. Gurbel, P.A.; Bliden, K.P.; Hiatt, B.L.; O'Connor, C.M. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 2003, 107, 2908-13.
8. O'Donoghue, M.; Wiviott, S.D. Clopidogrel response variability and future therapies: Clopidogrel: Does one size fit all? Circulation, 2006, 114, 600-606.
9. Angiolillo, D.J.; Fernandez-Ortiz, A.; Bernardo, E.; Alfonso, F.; Macaya, C.; Bass, T.A.; Costa, M.A. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J. Am. Coll. Cardiol., 2007, 49, 1505-16.
10. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. J. Am. Coll. Cardiol., 2006, 47, 1-121.
11. Tousoulis, D.; Siasos, G.; Stefanadis, C. Aspirin resistance: What the cardiologist needs to know? Int. J. Cardiol., 2009, 132, 153-6.
12. Antman, E.M.; Hand, M.; Armstrong, P.W.; Bates, E.R.; Green, L.A.; Halasyamani, L.K.; Hochman, J.S.; Krumholz, H.M.;, Lamas, G.A.; Mullany, C.J.; Pearle, D.L.; Sloan, M.A.; Smith, S.C.Jr.; Anbe, D.T.; Kushner, F.G.; Ornato, J.P.; Pearle, D.L.; Sloan, M.A.; Jacobs, A.K.; Adams, C.D.; Anderson, J.L.; Buller, C.E.; Creager, M.A.; Ettinger, S.M.; Halperin, J.L.; Hunt, S.A.; Lytle, B.W.; Nishimura, R.; Page, R.L.; Riegel, B.; Tarkington, L.G.; Yancy, C.W. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2008, 51, 210-47.
13. Anderson, J.L.; Adams, C.D.; Antman, E.M.; Bridges, C.R.; Califf, R.M.; Casey, D.E.Jr.; Chavey, W.E. 2nd.; Fesmire, F.M.; Hochman, J.S.; Levin, T.N.; Lincoff, A.M.; Peterson, E.D.; Theroux, P.; Wenger, N.K.;, Wright, R.S.; Smith, S.C.Jr.; Jacobs, A.K.; Halperin, J.L.; Hunt, S.A.; Krumholz, H.M.; Kushner, F.G.; Lytle, B.W.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation, 2007, 116, 148-304.
14. Ahn, T.; Kim, M.; Yun, C.H.; Chae, H.J. Functional regulation of hepatic cytochrome p450 enzymes by physicochemical properties of phospholipids in biological membranes. Curr. Protein Pept. Sci., 2007, 8, 496-505.
15. Kalgutkar, A.S.; Obach, R.S.; Maurer, T.S. Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drugdrug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab., 2007, 8, 407-47.
16. Ma, T.K.; Lam, Y.Y.; Tan, V.P.; Kiernan, T.J.; Yan, B.P. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacol. Ther., 2010, 125, 249-59.
17. Snider, N.T.; Walker, V.J.; Hollenberg, P.F. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: Physiological and pharmacological implications. Pharmacol. Rev., 2010, 62, 136-54
18. Niwa, T.; Murayama, N.; Yamazaki, H. Oxidation of endobiotics mediated by xenobiotic metabolizing forms of human cytochrome. Curr. Drug Metab., 2009, 10, 700-12.
19. Guengerich, F.P. Drug Metab. Rev., 2004, 36, 159-197.
20. Shimada, T.; Oda, Y.; Gillam, E.M.; Guengerich, F.P.; Inoue, K. Drug Metab. Dispos., 2001, 29, 1176-1182.
21. Tousoulis, D.; Paroutoglou, I.P.; Papageorgiou, N.; Charakida, M.; Stefanadis, C. Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacol. Ther., 2010, 127, 108-20.
22. Arrebola, M.M.; De la Cruz, J.P.; Villalobos, M.A.; Pinacho, A.; Guerrero, A.; Sánchez de la Cuesta, F. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J. Cardiovasc. Pharmacol., 2004, 43, 74-82.
23. Ciuffetti, G.; Lombardini, R.; Pirro, M.; Lupattelli, G.; Mannarino, E. Clopidogrel: Hemorheological effects in subjects with subclinical atherosclerosis. Clin. Hemorheol. Microcirc., 2001, 25, 31-9.
24. Steinhubl, S.R.; Moliterno, D.J. The role of the platelet in the pathogenesis of atherothrombosis. Am. J. Cardiovasc. Drugs, 2005, 5, 399-408.
25. Judge, H.M.; Patil, S.B.; Buckland, R.J.; Jakubowski, J.A.; Storey, R.F. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation following clopidogrel. J. Thromb. Haemost., 2010.
26. Pereillo, J.M.; Maftouh, M.; Andrieu, A.; Uzabiaga, M.F.; Fedeli, O.; Savi, P.; Pascal, M.; Herbert, J.M.; Maffrand, J.P.; Picard, C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos., 2002, 30, 1288-95.
27. Siller-Matula, J.; Schrör, K.; Wojta, J.; Huber, K. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. Thromb. Haemost., 2007, 97, 385-93.
28. Combescure, C.; Fontana, P.; Mallouk, N.; Berdague, P.; Labruyere, C.; Barazer, I.; Gris, J.C.; Laporte, S.; Fabbro-Peray, P.; Reny, J.L. Clinical implications of clopidogrel non-response in cardiovascular patients: A systematic review and meta-analysis. J. Thromb. Haemost., 2010, 8, 923-33.
29. Angiolillo, D.J.; Alfonso, F. Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure. Thromb. Haemost., 2007, 98, 707-9.
30. Tousoulis, D.; Briasoulis, A.; Dhamrait, S.S.; Antoniades, C.; Stefanadis, C. Heart, 2009, 95, 850-8.
31. Michos, E.D.; Ardehali, R.; Blumenthal, R.S.; Lange, R.A.; Ardehali, H. Aspirin and clopidogrel resistance. Mayo Clin. Proc., 2006, 81, 518-26.
32. Giuliano, R.P.; Braunwald, E. The year in non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol., 2005, 46, 906-19.
33. Nguyen, T.A.; Diodati, J.G.; Pharand, C. Resistance to clopidogrel: A review of the evidence. J. Am. Coll. Cardiol., 2005, 45, 1157-64.
34. Wiviott, S.D.; Antman, E.M. Clopidogrel resistance. A new chapter in a fast-moving story. Circulation, 2004, 109, 3064-7.
35. Wang, T.H.; Bhatt, D.L.; Topol, E.J. Aspirin and clopidogrel resistance: An emerging clinical entity. Eur. Heart J., 2006, 27, 647-54.
36. Guthikonda, S.; Lev, E.I.; Kleinman, N.S. Resistance to antiplatelet therapy. Curr. Cardiol. Reports, 2005, 7, 242-8.
37. Bates, E.; Lau, W.C. Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation, 2005, 111, 267-71.
38. Matetzky, S.; Shenkman, B.; Guetta, V.; Schechter, M.; Bienart, R.; Goldenberg, I.; Novikov, I.; Pres, H.; Savion, N.; Varon, D.; Hod, H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 2004, 109, 3171-5.
39. Lau, W.C.; Gurbel, .PA.; Watkins, P.B.; Neer, C.J.; Hopp, A.S.; Carville, D.G.M.; Guyer, K.E.; Tait, A.R.; Bates, E.R. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation, 2004, 109, 166-71.
40. Angiolillo, D.J.; Fernandez-Ortiz, A.; Bernardo, E.; Alfonso, F.; Sabaté, M.; Fernández, C.; Stranieri, C.; Trabetti, E.; Pignatti, P.F.; Macaya, C. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul. Fibrinolysis, 2004, 15, 89-93.
41. Angiolillo, D.J.; Fernandez-Ortiz, A.; Bernardo, E.; Ramírez, C.; Cavallari, U.; Trabetti, E.; Sabaté, M.; Hernández, R.; Moreno, R.; Escaned, J.; Alfonso, F.; Bañuelos, C.; Costa, M.A.; Bass, T.A.; Pignatti, P.F.; Macaya, C. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 1895-900.
42. Brandt, J.T.; Close, S.L.; Iturria, S.J.; Payne, C.D.; Farid, N.A.; Ernest, C.S. 2nd.; Lachno, D.R.; Salazar, D.; Winters, K.J. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost., 2007, 5, 2429-36.
43. Fontana, P.; Dupont, A.; Gandrille, S.; Bachelot-Loza, C.; Reny, J.L.; Aiach, M.; Gaussem, P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation, 2003, 108, 989-95.
44. Giusti, B.; Gori, A.M.; Marcucci, R.; Saracini, C.; Sestini, I.; Paniccia, R.; Valente, S.; Antoniucci, D.; Abbate, R.; Gensini, G.F. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics, 2007, 17, 1057-64.
45. Hulot, J.S.; Bura, A.; Villard, E.; Azizi, M.; Remones, V.; Goyenvalle, C.; Aiach, M.; Lechat, P.; Gaussem, P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 2006, 108, 2244-7.
46. Trenk, D.; Hochholzer, W.; Fromm, M.F.; Chialda, L.E.; Pahl, A.; Valina, C.M.; Stratz, C.; Schmiebusch, P.; Bestehorn, H.P.; Büttner, H.J.; Neumann, F.J. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol., 2008, 51, 1925-34.
47. Siasos, G.; Tousoulis, D.; Stefanadis, C. Multiple mechanisms affect the clopidogrel response. J. Am. Coll. Cardiol., 2009, 53, 900-1.
48. Tousoulis, D.; Briasoulis, A.; Papageorgiou, N.; Antoniades, C.; Stefanadis, C. Candidate gene polymorphisms and the 9p21 locus in acute coronary syndromes. Trends. Mol. Med., 2008, 14, 441-9.
49. Taubert, D.; von Beckerath, N.; Grimberg, G.; Lazar, A.; Jung, N.; Goeser, T.; Kastrati, A.; Schömig, A.; Schömig, E. Impact of Pglycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther., 2006, 80, 486-501.
50. Clarke, T.A.; Waskell, L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos., 2003, 31, 53-59.
51. Lins, R.; Broekhuysen, J.; Necciari, J.; Deroubaix, X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin. Thromb. Hemost., 1999, 25, 29-33.
52. Savi, P.; Pereillo, J.M.; Uzabiaga, M.F.; Combalbert, J.; Picard C, Maffrand JP, PascalM, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost., 2000, 84, 891-6.
53. Kurihara, A.; Hagihara, K.; Kazui, M.; Ishizuka, T.; Farid, N.A.; Ikeda, T. In vitro metabolism of antiplatelet agent clopidogrel: Cytochrome P450 isoforms responsible for two oxidation steps involved in active metabolite formation. Drug Metab Rev., 2005, 37, 99.
54. Farid, N.A.; Payne, C.D.; Small, D.S.; Winters, K.J.; Ernest, C.S.; Brandt, J.T.; Darstein, C.; Jakubowski, J.A.; Salazar, D.E. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther., 2007, 81, 735-41.
55. Ding, Z.; Kim, S.; Dorsam, R.T.; Jin, J.; Kunapuli, S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood, 2003, 101, 3908-14.
56. Xiao, Z.; Theroux, P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J. Am. Coll. Cardiol., 2004, 43, 1982-8.
57. Hermann, A.; Rauch, B.H.; Braun, M.; Schror, K.; Weber, A.A. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets, 2001, 12, 74-82.
58. Vivekananthan, D.P.; Bhatt, D.L.; Chew, D.P.; Zidar, F.J.; Chan, A.W.; Moliterno, D.J.; Ellis, S.G.; Topol. E.J. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am. J. Cardiol., 2004, 94, 358-60.
59. Gurbel, P.A.; Bliden, K.P.; Guyer, K.; Aggarwal, N.; Tantry, U.S. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb. Res., 2007, 119, 563-70.
60. Labarthe, B.; Theroux, P.; Angioi, M.; Ghitescu, M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J. Am. Coll. Cardiol., 2005, 46, 638-45.
61. Storey, R.F.; Judge, H.M.; Wilcox, R.G.; Heptinstall, S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb. Haemost., 2002, 88, 488-94.
62. Jakubowski, A.; Chlopicki, S.; Olszanecki, R.; Jawien, J.; Lomnicka, M.; Dupin, J.P.; Gryglewski, R.J. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins. Leukot. Essent. Fatty Acids, 2005, 72, 139-45.
63. Warnholtz, A.; Ostad, M.A.; Velich, N.; Trautmann, C.; Schinzel, R.; Walter, U.; Munzel, T. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: Results of a doubleblind, randomized study. Atherosclerosis, 2008, 196, 689-95.
64. Ziemianin, B.; Olszanecki, R.; Uracz, W.; Marcinkiewicz, E.; Gryglewski, R.J. Thienopyridines: Effects on cultured endothelial cells. J. Physiol. Pharmacol., 1999, 50, 597-604.
65. Lev, E.I.; Patel, R.T.; Maresh, K.J.; Guthikonda, S.; Granada, J.; DeLao, T.; Bray, P.F.; Kleiman, N.S. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: The role of dual drug resistance. J. Am. Coll. Cardiol., 2006, 47, 27-33.
66. Gurbel, P.A.; Bliden, K.P.; Guyer, K.E.; Cho, P.W.; Zaman, K.A.; Kreutz, R.P.; Bassi, A.K.; Tantry, U.S. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE Post-Stenting study. J. Am. Coll. Cardiol., 2005, 46, 1820-1826.
67. Gurbel, P.A.; Bliden, K.P.; Zaman, K.A.; Yoho, J.A.; Hayes, K.M.; Tantry, U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation, 2005, 111, 1153-1159.
68. Cuisset, T.; Frere, C.; Quilici, J.; Barbou, F.; Morange, P.E.; Hovasse, T.; Bonnet, J.L.; Alessi, M.C. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost., 2006, 4, 542-549.
69. Cuisset, T.; Frere, C.; Quilici, J.; Morange, P.E.; Nait-Saidi, L.; Carvajal, J.; Lehmann, A.; Lambert, M.; Bonnet, J.L.; Alessi, M.C. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol., 2006, 48, 1339-1345.
70. Hochholzer, W.; Trenk, D.; Bestehorn, H.P.; Fischer, B.; Valina, C.M.; Ferenc, M.; Gick, M.; Caputo, A.; Büttner, H.J.; Neumann, F.J. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective stent placement. J. Am. Coll. Cardiol., 2006, 48, 1742-1750.
71. Geisler, T.; Langer, H.; Wydymus, M.; Göhring, K.; Zürn, C.; Bigalke, B.; Stellos, K.; May, A.E.; Gawaz, M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart. J., 2006, 27, 2420-2425.
72. Bliden, K.P.; DiChiara, J.; Tantry, U.S.; Bassi, A.K.; Chaganti, S.K.; Gurbel, P.A. Increased risk in patients with thigh platelet aggregation on chronic clopidogrel therapy undergoing PCI: Is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol., 2007, 49, 657-666.
73. Cuisset, T.; Frere, C.; Quilici, J.; Morange, P.E.; Nait-Saidi, L.; Mielot, C.; Bali, L.; Lambert, M.; Alessi, M.J.; Bonnet, J.L. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb. Haemost., 2007, 97, 282-287.
74. Bonello, L.; Paganelli, F.; Arpin-Bornet, M.; Auguier, P.; Sampol, J.; Dignat- George, F.; Barragan, P.; Camoin-Jau, L. Vasodilatorstimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost., 2007, 5, 1630-1636.
75. Angiolillo, D.J.; Bernardo, E.; Sabaté, M.; Jimenez-Quevedo, P.; Costa, M.A.; Palazuelos, J.; Hernández-Antolin, R.; Moreno, R.; Escaned, J.; Alfonso, F.; Bañuelos, C.; Guzman, L.A.; Bass, T.A.; Macaya, C.; Fernandez-Ortiz, A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol., 2007, 50, 1541-1547.
76. Frere, C.; Cuisset, T.; Quilici, J.; Camoin, L.; Carvajal, J.; Morange, P.E.; Lambert. M.; Juhan-Vague, I.; Bonnet, J.L.; Alessi, M.C. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost., 2007, 98, 838-843.
77. Angiolillo, D.J. Variability in Responsiveness to Oral Antiplatelet Therapy Am. J. Cardiol., 2009, 103, 27A-34A.
78. de Morais, S.M.; Wilkinson, G.R.; Blaisdell, J.; Nakamura, K.; Meyer, U.A.; Goldstein, J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 1994, 269, 15419-22.
79. Goldstein, J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Brit. J. Clin. Pharmacol., 2001, 52, 349-55.
80. Desta, Z.; Zhao, X,; Shin, J.G.; Flockhart, D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet., 2002, 41, 913-58.
81. Varenhorst, Ch.; James, St.; Erlinge, D.; Brandt, J.T.; Braun, O.; Man, M.; Siegbahn, A.; Walker, J.; Wallentin, L.;Winters, K.J.; Close, S.L. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur. Heart J., 2009, 30, 1744-175232.
82. von Beckerath, N.; Taubert, D.; Pogatsa-Murray, G.; Wieczorek, A.; Schömig, E.; Schömig, A.; Kastrati A. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb. Haemost., 2005, 93,789-91.
83. Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Hockett, R.D.; Brandt, J.T.; Walker, J.R.; Antman, E.M.; Macias, W.; Braunwald, E.; Sabatine, M.S. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 2009, 360, 354-362.
84. von Beckerath, N.; Taubert, D.; Pogatsa-Murray, G.; Schömig, E.; Kastrati, A.; Schömig, A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation, 2005, 112, 2946-50.
85. Brandt, J.T.; Payne, C.D.; Wiviott, S.D.; Weerakkody, G.; Farid, N.A.; Small, D.S.; Jakubowski, J.A.; Naganuma, H.; Winters, K.J. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J., 2007, 153, e6916.
86. Wallentin, L.; Varenhorst. C.; James, S.; Erlinge, D.; Braun, O.O.; Jakubowski, J.A.; Sugidachi, A.; Winters, K.J.; Siegbahn. A. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J., 2008, 29, 21-30.
87. Fontana, P.; Hulot, J.S.; De Moerloose, P.; Gaussem, P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J. Thromb. Haemost., 2007, 5, 2153-2155.
88. Frere, C.; Cuisset, T.; Morange, P.E.; Quilici, J.; Camoin-Jau, L.; Saut, N.; Faille, D.; Lambert, M.; Juhan-Vague, I.; Bonnet, J.L.; Alessi, M.C. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndromes. Am. J. Cardiol., 2008, 101, 1088-1093.
89. Giusti, B.; Gori, A.M.; Marcucci, R.; Saracini, C.; Sestini, I.; Paniccia, R.; Buonamici, P.; Antoniucci, D.; Abbate, R.; Gensini, G.F. Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis. Am. J. Cardiol., 2009, 103, 806-811.
90. Collet, J.P.; Hulot, J.S.; Pena, A.; Villard, E.; Esteve, J.B.; Silvain, J.; Payot, L.; Brugier, D. Cayla, G.; Beygui, F.; Bensimon, G.; Funck-Brentano, C.; Montalescot, G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet, 2009, 373, 309-17.
91. Simon, T.; Verstuyft, C.; Mary-Krause, M.; Quteineh, L.; Drouet, E.; Méneveau, N.; Steg, P.G.; Ferriéres, J.; Danchin, N.; Becquemont, L. The French Registry of Acute ST-Elevation Non-STElevation Myocardial Infarction (FAST-MI) Investigators.Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 2009, 360, 363-375.
92. Sibbing, D.; Koch, W.; Gebhard, D.; Schuster, T.; Braun, S.; Stegherr, J.; Morath, T.; Schömig, A.; von Beckerath, N.; Kastrati A. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation, 2010, 121, 512-518.
93. Gladding, P.; Webster, M.; Zeng, I.; Farrell, H.; Stewart, J.; Ruygrok, P.; Ormiston, J.; El-Jack, S.; Armstrong, G.; Kay, P.; Scott, D.; Gunes, A.; Dahl, M.L. The pharmacogenetics and pharmacodynamics of clopidogrel response : An analysis from the PRINC (Plavix Response in Coronary Intervention ) trial. J. Am. Coll. Cardiol. Intv., 2008, 1, 620-7.
94. Lee, J.M.; Park, S.; Shin, D.J.; Choi, D.; Shim, C.Y.; Ko, Y.G.; Kim, J.S.; Shin, E.S.; Chang, C.W.; Lee, J.E.; Jang, Y. Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans Am. J. Cardiol., 2009, 104, 46-51.
95. Bertrand-Thiébault, C.; Berrahmoune, H.; Thompson, A.; Marie, B.; Droesch, S.; Siest, G.; Foernzler, D.; Visvikis-Siest, S. Genetic polymorphism of CYP2C19 gene in the stanislas cohort. A link with inflammation. Ann. Hum. Genet., 2008, 72, 178-83.
96. Clarke, T.A.; Waskell, L.A. The metabolism of clopidogrel is catalized by human cyto hrome 450 3A and is inhibited by atorvastatin. Drug Metab. Dispos., 2003, 31, 53-9.
97. Evans, W.E.; McLeod, H.L. Pharmacogenomics: Drug disposition, drug targets, and side effects. N. Engl. J. Med., 2003, 348, 538-49.
98. Suh, J.W.; Koo, B.K.; Zhang, S.Y.; Park, K.W.; Cho, J.Y.; Jang, I.J.; Lee, D.S.; Sohn, D.W.; Lee, M.M.; Kim, H.S. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ., 2006, 174, 1715-22.
99. Harmsze, A.; van Werkum, J.W.; Bouman, H.J.; Ruven, H.J.; Breet, N.J.; Ten Berg, J.M.; Hackeng, C.M.; Tjoeng, M.M.; Klungel, O.H.; de Boer, A.; Deneer, V.H. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet. Genomics, 2010, 20, 18-25.
100. Patti, G.; Colonna, G.; Pasceri, V.; Pepe, L.L.; Montinaro, A.; Di Sciascio, G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation, 2005, 111, 2099-2106.
101. Dangas, G.; Mehran, R.; Guagliumi, G.; Caixeta, A.; Witzenbichler, B.; Aoki, J.; Peruga, J.Z.; Brodie, B.R.; Dudek, D.; Kornowski, R.; Rabbani, L.E.; Parise, H.; Stone, G.W.; HORIZONS-AMI Trial Investigators. Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONSAMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J. Am. Coll. Cardiol., 2009, 54, 1438-46.
102. Montalescot, G.; Sideris, G.; Meuleman, C.; Bal-dit-Sollier, C; Lellouche, N.; Steg, P.G.; Slama, M.; Milleron, O.; Collet, J.P.; Henry, P.; Beygui, F.; Drouet, L.; for the ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol., 2006, 48, 931-938.
103. Price, M.J.; Coleman, J.L.; Steinhubl, S.R.; Wong, G.B.; Cannon, C.P.; Teirstein, P.S. Onset and offset of platelet inhibition after high dose clopidogrel loading and standard daily therapy measure by a point of care assay in healthy volunteers. Am. J. Cardiol., 2006, 98, 681-684.
104. Raju, N.C.; Eikelboom, J.W.; Hirsh, J. Platelet ADP-receptor antagonists for cardiovascular disease: Past, present and future. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5, 766-80.
105. Angiolillo, D.J.; Shoemaker, S.B.; Desai, B.; Yuan, H.; Charlton, R.K.; Bernardo, E.; Zenni, M.M.; Guzman, L.A.; Bass, T.A.; Costa, M.A. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation, 2007, 115, 708-716.
106. Angiolillo, D.J.; Costa, M.A.; Shoemaker, S.B.; Desai, B.; Bernardo, E.; Suzuki, Y.; Charlton, R.K.; Zenni, M.M.; Guzman, L.A.; Bass, T.A. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am. J. Cardiol., 2008, 101, 440-445.
107. Angiolillo, D.J.; Fernández-Ortiz, A.; Bernardo, E.; Ramírez, C.; Sabaté, M.; Bañuelos, C.; Hernández- Antolín, R.; Escaned, J.; Moreno, R.; Alfonso, F.; Macaya, C. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur. Heart J., 2004, 25, 1903-10.
108. Bonello, L.; Palot-Bonello, N.; Armero, S.; Camoin-Jau, L.; Paganelli, F. Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19*2 loss of function polymorphism. Int. J. Cardiol., 2009, [Epub ahead of print].
109. McGlasson, D.L.; Fritsma, G.A. Whole blood platelet aggregometry and platelet function testing. Semin. Thromb. Hemost., 2009, 35, 168-80.
110. Michelson, A.D. Platelet function testing in cardiovascular diseases. Circulation, 2004, 9, 110(19), e489-93.
111. Cattaneo, M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J. Thromb. Haemost., 2007, 5 Suppl 1, 230-7.
112. Harrison, P.; Frelinger, A.L. 3rd.; Furman, M.I.; Michelson, A.D. Measuring antiplatelet drug effects in the laboratory. Thromb. Res., 2007, 120, 323-36.
113. Cazenave, J.P.; Hemmendinger, S.; Beretz, A.; Sutter-Bay, A.; Launay, J. Platelet aggregation: A tool for clinical investigation and pharmacological study. Methodology. Ann. Biol. Clin., 1983, 41, 167-79.
114. Madsen, E.H.; Schmidt, E.B.; Maurer-Spurej, E.; Kristensen, S.R. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets, 2008, 19, 335-41.
115. Hayward, C.P.; Harrison, P.; Cattaneo, M.; Ortel, T.L.; Rao, A.K. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J. Thromb. Haemost., 2006, 4, 312-9.
116. Michelson, A.D. Evaluation of platelet function by flow cytometry. Pathophysiol. Haemost. Thromb., 2006, 35, 67-82.
117. van Werkum, J.W.; Harmsze, A.M.; Elsenberg, E.H.; Bouman, H.J.; ten Berg, J.M.; Hackeng, C.M. The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence. Platelets, 2008, 19, 479-88.